Saturday 17 October 2026 Export CLSDQ’s income statement to Excel — free account

Clearside Biomedical, Inc.

Clearside Biomedical, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $1.7 million, down 79.8% from fiscal 2023. In the quarter to September 2025, revenue fell 80.6%, EPS grew 24.0% and free cash flow grew 8.15%, each against the same quarter a year earlier.

0.25 0.00 0.00%

Follow CLSDQ

Alert me

Market cap: $2.2M
P/E: 0.0×
Fwd P/E: −0.1×
Dividend yield: —
F-score: 3/9
Altman Z: −22.08
Beneish M: −1.63
Dividend safety: n/a

Overview Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 20.33%

Capital & Financial Ratios $m

Market Cap 2.15

Revenue 3.33

Net Income (26.00)

Free Cash Flow (21.75)

Net Debt (6.80)

Current Ratio 2.98

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (0.14)

P/S ratio 0.39

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 34.04%

Next Y EPS Growth 29.03%

Next Y revenue growth 38.22%

Next 5Y EPS Growth 22.36%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2022	2023	2024	Q'25
Cash	48	29	20	7
Receivables	—	0	1	0
Inventory	—	—	—	—
Other	0	0	0	—
	49	30	21	8

	2022	2023	2024	Q'25
Payables	1	2	1	1
ST’ Debt	—	—	—	—
Other	—	—	—	—
	6	7	5	3

Compound Annual Growth %

	10y	5y	3y
Sales	—	(5.20%)	(61.68%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	0.00%	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	2	0	0	—	—
’24	0	0	1	0	2
’23	0	1	1	6	8
’22	0	0	0	0	1
’21	0	1	3	26	30
’20	4	0	3	0	8
’19	0	0	0	2	2

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(6)	(5)	(5)	—	—
’24	(8)	(6)	(6)	(5)	(25)
’23	(7)	(5)	(6)	0	(18)
’22	4	(5)	(6)	(6)	(13)
’21	(6)	(7)	(3)	5	(11)
’20	(3)	(3)	(3)	(4)	(13)
’19	(13)	(10)	(6)	2	(27)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(6)	(5)	(5)	—	—
’24	(8)	(6)	(6)	(6)	(26)
’23	(7)	(6)	(7)	0	(20)
’22	4	(5)	(6)	(6)	(14)
’21	(6)	(7)	(3)	5	(11)
’20	(3)	(3)	(3)	(4)	(13)
’19	(13)	(10)	(6)	2	(27)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(1.65)	(0.90)	(1.14)	—	—
’24	(2.55)	(1.50)	(1.50)	(1.50)	(7.05)
’23	(2.25)	(2.25)	(2.25)	(1.20)	(7.95)
’22	(1.95)	(1.95)	(1.95)	(2.40)	(8.25)
’21	(1.95)	(1.65)	(1.20)	4.65	0.09
’20	(1.05)	(1.95)	(0.75)	(2.10)	(5.85)
’19	(6.75)	(2.25)	(2.55)	(1.05)	(12.14)

Fiscal quarters ending in the months shown.

Group	Line	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025e
Price, $
Price, $	Low	—	84.75	81.60	14.85	8.40	16.50	33.15	14.70	9.75	12.02	Analyst estimates 2025–2027 Powerpack
	High	—	376.20	156.92	229.94	59.25	61.95	115.95	44.25	27.75	31.80
People
People	Employees	—	24	34	50	33	33	34	36	30	32
	Revenue/emp, $m	—	0.02	0.01	0.00	0.07	0.24	0.87	0.04	0.27	0.05
Income, $m
Income, $m	Revenue	—	1	0	0	2	8	30	1	8	2
	Gross margin, %	—	100.00	100.00	100.00	100.00	100.00	100.00	84.63	95.68	91.05
	EBT	—	(26)	(59)	(83)	(31)	(18)	0	(33)	(32)	(34)
	EBT margin, %	—	(4,977.31)	(17,094.20)	(276,060.00)	(1,416.01)	(230.68)	1.27	(2,482.82)	(394.91)	(2,064.42)
	Net income	—	(26)	(59)	(83)	(31)	(18)	0	(33)	(32)	(34)
	Depreciation	—	0	0	0	0	0	0	0	0	0
Per share, $
Per share, $	Revenue	—	0.59	0.20	0.01	0.85	2.54	7.58	0.33	2.00	0.34
	Earnings	—	(29.53)	(34.93)	(40.33)	(12.14)	(5.85)	0.10	(8.25)	(7.95)	(7.05)
	Cash flow	—	(25.97)	(30.26)	(38.63)	(10.63)	(4.23)	(2.75)	(3.33)	(4.40)	(5.02)
	Capex	—	0.00	(0.18)	(0.04)	(0.01)	(0.02)	0.00	(0.06)	(0.43)	(0.20)
	Free cash flow	—	(25.97)	(30.44)	(38.68)	(10.64)	(4.25)	(2.75)	(3.39)	(4.83)	(5.22)
	Book value	—	81.94	12.68	11.52	4.38	2.83	9.73	2.64	(3.86)	(7.89)
	Shares, m	—	1	2	2	3	3	4	4	4	5
Valuation, ×
Valuation, ×	P/E	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	236.37	527.78	95.37	50.97	16.15	5.44	55.17	9.70	42.16
	P/B	—	1.72	8.50	1.39	9.93	14.55	4.24	6.90	0.00	0.00
	EV/Sales	—	94.74	441.89	5.80	42.94	14.13	4.46	19.84	6.35	30.95
	EV/FCF	—	(2.17)	(2.97)	(0.03)	(3.44)	(8.47)	(12.22)	(1.93)	(2.62)	(2.01)
Cash, $m
Cash, $m	Operating cash flow	—	(23)	(51)	(79)	(27)	(13)	(11)	(13)	(18)	(25)
	Capex	—	0	0	0	0	0	—	0	(2)	(1)
	Free cash flow	—	(23)	(51)	(79)	(27)	(13)	(11)	(14)	(20)	(26)
Balance, $m
Balance, $m	Working capital	—	79	26	32	14	8	37	44	23	16
	Total debt	—	8	8	10	5	1	1	35	—	—
	Net debt	—	(76)	(30)	(31)	(17)	(16)	(30)	(48)	(29)	(20)
	Shareholders’ equity	—	72	21	24	11	9	38	11	(16)	(39)
Returns, %
Returns, %	ROA	—	(48.89)	(94.13)	(195.76)	(86.80)	(79.01)	1.21	(69.95)	(76.15)	(116.16)
	ROIC	—	0.00	0.00	0.00	0.00	0.00	(5.20)	0.00	0.00	0.00
	ROE	—	(147.90)	(126.73)	(367.79)	(176.96)	(182.83)	1.61	(135.63)	1,224.69	125.45

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2024 · latest quarter Sep 2025

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
MTNB Matinas Biopharma Holdings, Inc.	$2.4M	— (loss-making)	— (loss-making)	+365,433.33% (above 0%: growing)	n/m	+9.15% (above 0%: growing)	0.00%	0.00%	Compare
BPTSY Biophytis SA Sponsored ADR	$2.4M	— (loss-making)	—	—	n/m	+53.15% (above 0%: growing)	0.00%	—	Compare
WINT Windtree Therapeutics, Inc.	$2.4M	— (loss-making)	— (loss-making)	−100.00% (below 0%: shrinking)	n/m	+1.12% (above 0%: growing)	0.00%	0.00%	Compare
KAPA Kairos Pharma, Ltd.	$2.3M	— (loss-making)	—	—	n/m	−25.71% (below 0%: shrinking)	—	0.00%	Compare
VRAX Virax Biolabs Group Limited	$2.2M	— (loss-making)	— (loss-making)	—	−855.56% (below 0%: shrinking)	+32.24% (above 0%: growing)	(53.57%)	0.00%	Compare
CLSDQ Clearside Biomedical, Inc.	$2.2M	— (loss-making)	— (loss-making)	−80.64% (below 0%: shrinking)	n/m	+8.15% (above 0%: growing)	100.00%	(3,502.49%)
BRTX Biorestorative Therapies, Inc.	$2.0M	— (loss-making)	— (loss-making)	−7.20% (below 0%: shrinking)	n/m	−35.26% (below 0%: shrinking)	68.10%	(14,593.53%)	Compare
PPBT Purple Biotech Ltd. Sponsored ADR	$2.0M	— (loss-making)	— (loss-making)	—	n/m	−62.10% (below 0%: shrinking)	0.00%	0.00%	Compare
OGEN Oragenics, Inc.	$2.0M	0.4×	— (loss-making)	−75.33% (below 0%: shrinking)	n/m	−66.37% (below 0%: shrinking)	100.00%	0.00%	Compare
Median of peers	$2.2M	—	—	−41.26%	—	−12.29%	0.00%	0.00%

All 614 Biotechnology stocks →

Clearside Biomedical, Inc. (CLSDQ) key facts

Concern: Clearside Biomedical, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $1.7 million, down 79.8% from fiscal 2023.
Clearside Biomedical, Inc. (CLSDQ) is a Biotechnology company in the Healthcare sector.
As of July 22, 2026, CLSDQ traded at $0.25, a market capitalization of $2.2 million.
Return on equity was 125.5% and debt-to-equity 0.00.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −22.08 (distress zone) for fiscal 2024.

Source: company filings (standardised) and stockrow calculations.